Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 78,477Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Tafinlar

02 9Tafinlar/Mekinist

PharmaCompass

01

Brand Name : Tafinlar/Mekinist

Dabrafenib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,542

2019 Revenue in Millions : 1,338

Growth (%) : 15

blank

02

Brand Name : Tafinlar/Mekinist

Dabrafenib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,693

2020 Revenue in Millions : 1,542

Growth (%) : 10

blank

03

Brand Name : Tafinlar/Mekinist

Dabrafenib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,770

2021 Revenue in Millions : 1,693

Growth (%) : 5

blank

04

Brand Name : Tafinlar/Mekinist

Dabrafenib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,922

2022 Revenue in Millions : 1,770

Growth (%) : 9

blank

05

Brand Name : Tafinlar

Dabrafenib Mesylate

arrow
2024 ACI Convention
Not Confirmed

06

Brand Name : Tafinlar/Mekinist

Dabrafenib Mesylate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 453

Growth (%) : New Launch

blank

07

Brand Name : Tafinlar/Mekinist

Dabrafenib Mesylate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 672

2015 Revenue in Millions : 453

Growth (%) : 48

blank

08

Brand Name : Tafinlar/Mekinist

Dabrafenib Mesylate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 873

2016 Revenue in Millions : 672

Growth (%) : 30

blank

09

Brand Name : Tafinlar/Mekinist

Dabrafenib Mesylate

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib Mesylate

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 1,155

2017 Revenue in Millions : 873

Growth (%) : 32%

blank

10

Brand Name : Tafinlar/Mekinist

Dabrafenib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
2024 ACI Convention
Not Confirmed

Dabrafenib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,338

2018 Revenue in Millions : 1,155

Growth (%) : 16

blank